

Ovarian Cancer Cytogenomics and Nuclear Motors


Aakila Sammy¹ & Joanna Bridger¹

¹ College of Health & Life Sciences, Department of Life Sciences, Brunel University London, UK

20% of women with ovarian cancer **CANNOT RECEIVE TREATMENT** due to late diagnosis and ineffective treatment

The genome is **non-randomly** organised into **territories** but can **re-organise** in response to changes in physiological conditions and cell cycle. **Mis-localisation** can also occur in **disease** such as cancers.

Mapping chromosomes and gene loci position using **Fluorescence in-situ Hybridisation (FISH)** and erosion analysis.



Investigate mis-localisation of chromosomes and genes to produce a **biomarker panel** for a **diagnostic** FISH kit.

Treat and **induce drug resistance** on ovarian cancer cell lines to investigate the possibility of **adaptive or faster** re-organisation.


Temporarily remove the **motor ability** of the genome to re-organise via nuclear myosin RNA interference (RNAi) to **slow drug resistance**.

Treatment assays to investigate **lower drug** doses of **chemo-toxic** drugs in **combination** with nuclear myosin RNAi.

Monitor nuclear myosin **quantity** and **patterns** using western blot and indirect immunofluorescence


Diagnosing ovarian cancer **earlier** whilst **combating** drug **resistance** and **toxicity** using cytogenomics

Results



2D radial positioning of chromosome 10 and X imaged using FISH

Chromosome 10 and X occupancy from periphery to interior (1-5)



1 - periphery
2, 3, 4 - intermediate
5 - central

Conclusion

Genome organisation represents another level of control; an **exploitable mechanism**, in which nuclear motor myosin may play a significant **clinical role** in future diagnostics, prognostics and therapy



Find out more information and download this poster from here